TY - JOUR
T1 - Escape from neutralizing antibodies 1 by SARS-CoV-2 spike protein variants
AU - Weisblum, Yiska
AU - Schmidt, Fabian
AU - Zhang, Fengwen
AU - DaSilva, Justin
AU - Poston, Daniel
AU - Lorenzi, Julio C.C.
AU - Muecksch, Frauke
AU - Rutkowska, Magdalena
AU - Hoffmann, Hans Heinrich
AU - Michailidis, Eleftherios
AU - Gaebler, Christian
AU - Agudelo, Marianna
AU - Cho, Alice
AU - Wang, Zijun
AU - Gazumyan, Anna
AU - Cipolla, Melissa
AU - Luchsinger, Larry
AU - Hillyer, Christopher D.
AU - Caskey, Marina
AU - Robbiani, Davide F.
AU - Rice, Charles M.
AU - Nussenzweig, Michel C.
AU - Hatziioannou, Theodora
AU - Bieniasz, Paul D.
N1 - Generated from Scopus record by KAUST IRTS on 2023-02-15
PY - 2020/10/1
Y1 - 2020/10/1
N2 - Neutralizing antibodies elicited by prior infection or vaccination are likely to be key for future protection of individuals and populations against SARS-CoV-2. Moreover, passively administered antibodies are among the most promising therapeutic and prophylactic anti-SARS-CoV-2 agents. However, the degree to which SARS-CoV-2 will adapt to evade neutralizing antibodies is unclear. Using a recombinant chimeric VSV/SARS-CoV-2 reporter virus, we show that functional SARS-CoV-2 S protein variants with mutations in the receptor binding domain (RBD) and N-terminal domain that confer resistance to monoclonal antibodies or convalescent plasma can be readily selected. Notably, SARS-CoV-2 S variants that resist commonly elicited neutralizing antibodies are now present at low frequencies in circulating SARS-CoV-2 populations. Finally, the emergence of antibody-resistant SARS-CoV-2 variants that might limit the therapeutic usefulness of monoclonal antibodies can be mitigated by the use of antibody combinations that target distinct neutralizing epitopes.
AB - Neutralizing antibodies elicited by prior infection or vaccination are likely to be key for future protection of individuals and populations against SARS-CoV-2. Moreover, passively administered antibodies are among the most promising therapeutic and prophylactic anti-SARS-CoV-2 agents. However, the degree to which SARS-CoV-2 will adapt to evade neutralizing antibodies is unclear. Using a recombinant chimeric VSV/SARS-CoV-2 reporter virus, we show that functional SARS-CoV-2 S protein variants with mutations in the receptor binding domain (RBD) and N-terminal domain that confer resistance to monoclonal antibodies or convalescent plasma can be readily selected. Notably, SARS-CoV-2 S variants that resist commonly elicited neutralizing antibodies are now present at low frequencies in circulating SARS-CoV-2 populations. Finally, the emergence of antibody-resistant SARS-CoV-2 variants that might limit the therapeutic usefulness of monoclonal antibodies can be mitigated by the use of antibody combinations that target distinct neutralizing epitopes.
UR - https://elifesciences.org/articles/61312
UR - http://www.scopus.com/inward/record.url?scp=85096589275&partnerID=8YFLogxK
U2 - 10.7554/eLife.61312
DO - 10.7554/eLife.61312
M3 - Article
SN - 2050-084X
VL - 9
JO - eLife
JF - eLife
ER -
